Revue De Medecine InternePub Date : 2026-03-01Epub Date: 2026-02-26DOI: 10.1016/j.revmed.2026.02.003
Aïcha Kante , Jonathan Sormani , Anaïs Roeser
{"title":"Portrait du Pr. Arsène Mekinian, PU-PH et fondateur de l’ONG Santé Arménie","authors":"Aïcha Kante , Jonathan Sormani , Anaïs Roeser","doi":"10.1016/j.revmed.2026.02.003","DOIUrl":"10.1016/j.revmed.2026.02.003","url":null,"abstract":"","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"47 3","pages":"Pages 165-167"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147429224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chez les sujets présentant un risque cardiovasculaire élevé, atteints d’athérosclérose ou de diabète, mais n’ayant jamais subi d’infarctus du myocarde ou d’accident vasculaire cérébral, est-ce que le traitement par évolocumab entraîne une réduction des événements cardiovasculaires majeurs comparativement au placebo, tout en étant sécuritaire ?","authors":"Luc Lanthier , Alexandre Mutchmore , Marc-Émile Plourde , Michel Cauchon","doi":"10.1016/j.revmed.2026.01.002","DOIUrl":"10.1016/j.revmed.2026.01.002","url":null,"abstract":"","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"47 3","pages":"Pages 163-164"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147429223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Revue De Medecine InternePub Date : 2026-03-01Epub Date: 2025-10-27DOI: 10.1016/j.revmed.2025.10.003
Noémie Gensous , Mehdi Boubaddi , Bruno Lapuyade , Christophe Laurent , Pierre Duffau
{"title":"L’hémangiome géant du foie : une cause rare de fièvre prolongée inexpliquée","authors":"Noémie Gensous , Mehdi Boubaddi , Bruno Lapuyade , Christophe Laurent , Pierre Duffau","doi":"10.1016/j.revmed.2025.10.003","DOIUrl":"10.1016/j.revmed.2025.10.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Prolonged fever of unknown origin (FUO) is a complex diagnostic entity, most commonly caused by infectious, neoplastic, or inflammatory conditions. Hepatic hemangiomas, although frequent and benign, are rarely implicated.</div></div><div><h3>Case report</h3><div>A 53-year-old woman was hospitalized for FUO. Imaging revealed a giant hepatic hemangioma with areas of necrosis and hemorrhage. In the absence of infectious, neoplastic, or autoimmune etiology, the hemangioma was considered the most likely cause of fever. Arterial embolization using lipiodol and bleomycin led to complete resolution of the fever, normalization of inflammatory markers, and significant tumor volume reduction.</div></div><div><h3>Conclusion</h3><div>Hemangiomas as a cause of FUO are extremely rare, typically associated with giant lesions and necrotic or hemorrhagic complications. While surgical resection is the standard treatment, our case suggests that embolization may offer an effective and less invasive alternative.</div></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"47 3","pages":"Pages 156-160"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145395870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Revue De Medecine InternePub Date : 2026-03-01Epub Date: 2026-02-09DOI: 10.1016/j.revmed.2026.01.005
Alexandre Mercier-Guery , Vincent Petit , Arthur Bert , Amélie Delbende , Valentine Loustau , Romain Euvrard
{"title":"Étude rétrospective sur la supplémentation en fer intraveineux en hôpital de jour de médecine interne au sein d’un centre hospitalier régional","authors":"Alexandre Mercier-Guery , Vincent Petit , Arthur Bert , Amélie Delbende , Valentine Loustau , Romain Euvrard","doi":"10.1016/j.revmed.2026.01.005","DOIUrl":"10.1016/j.revmed.2026.01.005","url":null,"abstract":"<div><h3>Background</h3><div>Internal medicine day hospitals are facing a growing demand for intravenous (IV) iron infusions. This study aimed to describe the clinical characteristics and underlying etiologies of patients receiving IV iron in this setting.</div></div><div><h3>Methods</h3><div>A retrospective, single-center study was conducted over a one-year period in an internal medicine day hospital. Data collected included prescriber specialty, patient demographics, etiological work-up, prior treatments, and treatment tolerance. Multivariate analysis was performed to identify risk factors associated with repeated infusions.</div></div><div><h3>Results</h3><div>We included 158 patients (88% women; median age 44 [36–53] years). An etiology was identified in 89%; the main causes were gynecological (51% of women), post-bariatric surgery malabsorption (17%), and gastrointestinal causes (16%). Prior oral iron was documented in 57%. In the gynecological subgroup, 37% had non-mechanical contraception and 43% received an antifibrinolytic. Repeated infusions involved 59/155 (38%). Patients with repeated infusions were older (47 vs 40.5 years; <em>P</em> <!-->=<!--> <!-->0.02); other comparisons were not significant. In age and sex-adjusted models, age remained weakly associated (OR 1.02 [1.00–1.05]; <em>P</em> <!-->=<!--> <!-->0.03), with no significant relationship for other variables. In the multivariate model using forced age and sexe and forward AIC selection of other variables, ferritin (OR 1.02 [0.99–1.05]; <em>P</em> <!-->=<!--> <!-->0.14) and bariatric etiology (OR 2.21 [0.87–5.58]; <em>P</em> <!-->=<!--> <!-->0.09) were retained but however not reaching significancy. Adverse events were recorded in 150 patients: 3% overall (2% allergic, 1% non-allergic).</div></div><div><h3>Conclusion</h3><div>These findings highlight two populations addressed in internal medicine day hospital for iron IV: on the one hand, young women with heavy uterine bleeding, on the other hand, patients suffering from malabsorption following bariatric surgery. Reinforcing the role of primary care— in particular contraception, antifibrinolytic use, etiological investigation, and nutritional follow-up after bariatric surgery — is essential to prevent avoidable iron deficiency and improve long-term management.</div></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"47 3","pages":"Pages 119-126"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Revue De Medecine InternePub Date : 2026-03-01Epub Date: 2026-03-03DOI: 10.1016/j.revmed.2026.02.004
Baptiste Gramont
{"title":"Péricardite : un nouveau paradigme ?","authors":"Baptiste Gramont","doi":"10.1016/j.revmed.2026.02.004","DOIUrl":"10.1016/j.revmed.2026.02.004","url":null,"abstract":"","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"47 3","pages":"Pages 117-118"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Revue De Medecine InternePub Date : 2026-03-01Epub Date: 2025-11-05DOI: 10.1016/j.revmed.2025.09.006
Maxime Teisseyre , Marco Allinovi , Michael Levraut , Jacopo Lomi , Marion Cremoni , Barbara Seitz-Polski
{"title":"Anticorps anti-rituximab dans les maladies auto-immunes et les hémopathies malignes : mise au point","authors":"Maxime Teisseyre , Marco Allinovi , Michael Levraut , Jacopo Lomi , Marion Cremoni , Barbara Seitz-Polski","doi":"10.1016/j.revmed.2025.09.006","DOIUrl":"10.1016/j.revmed.2025.09.006","url":null,"abstract":"<div><div>Rituximab, a chimeric monoclonal antibody targeting the CD20, is a key therapy for treating haematological malignancies and numerous autoimmune diseases. However, its use may be complicated by the occurrence of anti-drug antibodies (ADA), which reflect its immunogenicity. This immunogenicity varies depending on the clinical context: it remains rare in oncology, but is more common in autoimmune diseases. These ADAs may be neutralising or non-neutralising and may influence pharmacokinetics, B-cell depletion, clinical efficacy and the risk of hypersensitivity reactions. Their occurrence is influenced by multiple factors: drug characteristics, administration methods, treatment regimen, but also patient-specific parameters. To limit immunogenicity, several approaches are being studied, such as optimising treatment regimens, combining with immunosuppressants, or using alternative humanised or fully human antibodies. This review provides an updated summary of anti-rituximab antibodies and highlights the importance of a personalised monitoring strategy to optimise the management of patients treated with rituximab.</div></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"47 3","pages":"Pages 147-155"},"PeriodicalIF":0.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}